PrecipioPRPO
About: Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Employees: 57
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
4.6% less ownership
Funds ownership: 8.84% [Q2] → 4.24% (-4.6%) [Q3]
33% less funds holding
Funds holding: 12 [Q2] → 8 (-4) [Q3]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
37% less capital invested
Capital invested by funds: $671K [Q2] → $422K (-$249K) [Q3]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for PRPO.
Financial journalist opinion
